Search

Your search keyword '"Zaccherini, Giacomo"' showing total 239 results

Search Constraints

Start Over You searched for: Author "Zaccherini, Giacomo" Remove constraint Author: "Zaccherini, Giacomo"
239 results on '"Zaccherini, Giacomo"'

Search Results

2. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis

3. Real-world experience with long-term albumin in patients with cirrhosis and ascites

6. FRI-078-YI Long-term albumin administration in outpatients with decompensated cirrhosis and diabetes mellitus: post-hoc analysis of the ANSWER trial database

7. FRI-171 Paediatric solid organ transplant recipients (SOTR) demonstrate greater serological response to initial SARS-CoV-2 vaccination than adult SOTR, and comparable rates of antibody degradation

8. FRI-047-YI Predictors of ascites resolution in patients with cirrhosis receiving long-term albumin treatment. Results from a real-world study in Italy (Real-ANSWER)

9. Long‐term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial.

10. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis

11. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis

13. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis.

14. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial

18. Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids

19. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide

23. Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study)

24. Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial

26. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.

27. Predictors of clinical trajectories of patients with acutely decompensated cirrhosis. An external validation of the PREDICT study.

28. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis

29. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)

30. Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study

31. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF

33. Correction and prevention of hyponatremia in patients with cirrhosis and ascites-post hoc analysis of the ANSWER study database

34. Clinical and pathophysiological characterization of patients with acutely decompensated cirrhosis and acute-on-chronic liver failure

35. Clinical and pathophysiological characterization of patients with acutely decompensated cirrhosis and acute-on-chronic liver failure

37. Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis

39. Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis

40. Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database.

41. Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register

44. O09 A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients

45. Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications

46. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

47. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF

48. Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature

49. Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry

50. WED-320 - Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study)

Catalog

Books, media, physical & digital resources